Publications

5539 Results

Dose-intense CHOPx2 therapy of intermediate grade lymphoma -- a phase II study of the Southwest Oncology Group (SWOG)

Authors
DW Blayney;M LeBlanc;RI Fisher
Journal / Conference
Blood 98(11):343a(#1448)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9349

A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800

Authors
DG Maloney;OW Press;RM Braziel;JM Unger;ML LeBlanc;TM Grogan;TP Miller;RI Fisher
Journal / Conference
Blood 98(11):843a(#3502)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
S9800

Cellular proteins determined by immunohistochemistry predict outcome in patients with aggressive non-Hodgkin's lymphoma: a first generation model of risk.

Authors
TP Miller;TM Grogan;J Unger;R Braziel;M Jaramillo;RI Fisher
Journal / Conference
Blood 98(11):125a(#526)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkins lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial.

Authors
TP Miller;M LeBlanc;C Spier;E Chase;RI Fischer
Journal / Conference
Blood 98(11):724a-725a(#3024)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8736 (INT-0093)

Prognostic implication of additional cytogenetic aberrations in denovo acute myeloid leukemia (AML) with t(15:17), t(8;21) or inv(16)/t(16;16).

Authors
PH Wiernik;H Kim;H Gundacker;G Dewald;ML Slovak;E Paietta;FR Appelbaum;MS Tallman
Journal / Conference
Blood 98(11):457a(#1913)
Year
2001
Research Committee(s)
Leukemia
Study Number(s)
SWOG-9007

The significance of trisomy 8 in myeloid leukemia: a Southwest Oncology Group (SWOG) study.

Authors
ML Slovak;H Gundacker;SR Wolman;FR Appelbaum
Journal / Conference
American Journal of Human Genetics 69(4):232(#285)
Year
2001
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8750, SWOG-9007, SWOG-9031, SWOG-9034 (EST-3489) (CALGB-9120), SWOG-9129 (INT-0129), SWOG-9333, SWOG-9500

Locally advanced nasopharyngeal cancer

Authors
JF Ensley;E Youseff;H Kim;G Yoo
Journal / Conference
Current Treatment Options in Oncology 2(1):15-23
Year
2001
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817)

Secondary analyis of RTOG 9310: an Intergroup phase II combined modality treatment of primary central nervous system lymphoma with chemotherapy and hyperfractionated radiotherapy

Authors
BJ Fisher;W Sieferheld;C Schultz;L De Angelis;D Nelson;SC Schold;W Curran
Journal / Conference
Int J Radiat Oncol Biol Phys 51(3):166(#297)
Year
2001
Research Committee(s)
Brain
Study Number(s)
SWOG-9310 (INT-0143) (RTOG-93-10)

Dietary supplement use in the prostate cancer prevention trial: implications for prevetion trials.

Authors
ML Neuhouser;AR Kristal;RE Patterson;PJ Goodman;IM Thompson
Journal / Conference
Nutrition and Cancer 39(1):12-18
Year
2001
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

Authors
WT Bellamy;L Richter;D Sirjani;C Roxas;B Glinsmann-Gibson;Y Frutiger;TM Grogan;AF List
Journal / Conference
Blood 97(5):1427-1434
Year
2001
Research Committee(s)
Leukemia